promotion image of download ymail app
Promoted
張西瓜 asked in 社會與文化語言 · 1 decade ago

『翻譯』醫學期刊英翻中!

Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells

The treatment of EBV-associated post-transplant lymphoproliferative disease (PTLD) poses a considerable challenge. Efforts have been made to define regimens based on combination of the available therapeutic agents, chosen and tailored on a patient-by-patient basis, with the aim of augmenting event-free patient and graft survival. Recently, autologous EBV-specific cytotoxic T-lymphocytes (CTL) have proved effective in enhancing EBV-specific immune responses and reducing viral load in organ transplant recipients with active infection. We investigated the use of a tailored combined approach including autologous EBV-specific CTL for the treatment of EBV-related PTLD developing after pediatric kidney transplantation. Five patients with disseminated monoclonal (n = 3) or localized polyclonal (n = 2) PTLD unresponsive to reduction of immunosuppression were enrolled. The patients with disseminated PTLD received 4-5 courses of reduced-dosage polychemotherapy, accompanied by rituximab on the first day of each course, while localized disease was removed surgically. At treatment completion, autologous EBV-specific CTL were infused. All patients showed a complete response to treatment, without therapy-related toxicity or rejection, and persist in remission with good renal function at a median follow-up of 31 months. These preliminary results suggest that a combined chemoimmunotherapy regimen including virus-specific T-cells is well tolerated and potentially effective as first-line treatment of EBV-related PTLD.

煩請簡單告訴我重點在哪

大概在說些什麼

不要翻譯軟體 謝謝喔:)

1 Answer

Rating
  • ivan
    Lv 7
    1 decade ago
    Favorite Answer

    Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells

    治療人類乳突病毒相關的腎臟移植手術後淋巴增生疾病,採用一種量身定製的治療方法,包括專門對抗乳突病毒的T細胞。

    全篇文章重點如下:

    一、治療﹁第四類乳突病毒︵EBV︶相關的腎臟移植手術後淋巴增生疾病(PTLD)﹂在醫學上是一大挑戰。採用量身定製的療法,結合現有的治療藥物,並選擇適合的病人,使病人能夠獲得有效治療,提高移植手術的存活率。

    二、自體EB病毒特異性細胞毒性T淋巴細胞(autologous EBV-specific cytotoxic T-lymphocytes (CTL))已被證明能有效地加強EB病毒特異性免疫,減少器官移植者遭病毒感染。

    三、我們研發為病人量身定製的組合方法,包括增強對付乳突病毒的T淋巴球細胞毒素,用於治療PTLD發展後,小兒腎移植。

    四、五位PTLD病人,可分成兩類,其中,兩人是單細胞繁殖,三人是局部多細胞繁殖的,結果他們對減少免疫抑制都能夠毫無反應︵也就是意味能夠提升免疫功能︶。

    五、所有病人在接受治療過程,顯示反應良好,沒有治療相關的毒性或排斥反應,在後續卅一個月的追蹤過程,病人的腎功能正常。

    六、從治療的結果,初步證明:結合化學免疫療法、包括對抗病毒特的特定T細胞,病人不但有很好的耐受性,做為第一線治療乳突病毒相關PTLD是有極佳的療效 。

    Source(s): 費心翻譯並重新整理
    • Commenter avatarLogin to reply the answers
Still have questions? Get your answers by asking now.